Last $6.94 USD
Change Today +0.84 / 13.77%
Volume 200.0
MDGEF On Other Exchanges
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDGEF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $9.59
52 Week Low
01/8/14 - $4.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIGENE AG (MDGEF)

Related News

No related news articles were found.

medigene ag (MDGEF) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDGEF) Details

Medigene AG, a biotechnology company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and breast cancer; and RhuDex, which is in Phase II clinical trial for the oral treatment of autoimmune diseases. It is also developing DC vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment is developing T cell receptor-(TCR) modified T cells, which is in pre-clinical trail for the treatment of advanced cancer; anti-TCR monoclonal antibodies that is in pre-clinical trail to treat T cell-mediated diseases, such as T cell leukaemia or auto-immune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines, which is in pre-clinical trials. It has strategic partnership with Syncore Biotechnologies Ltd. The company was founded in 1994 and is headquartered in Martinsried, Germany.

48 Employees
Last Reported Date: 03/27/14
Founded in 1994

medigene ag (MDGEF) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €563.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €390.0K
Compensation as of Fiscal Year 2013.

medigene ag (MDGEF) Key Developments

MeMediGene AG and Kora Healthcare Sign Agreement for the Commercialisation of Veregen in United Kingdom and Ireland

Medigene AG and Kora Healthcare concluded an exclusive agreement for the supply and commercialisation of Veregen(R) for the treatment of genital warts in United Kingdom and Ireland. Following marketing authorisation, Kora Healthcare will promote and distribute the drug for the treatment of genital warts. Medigene will receive a one-time upfront payment, revenues from milestone payments and from the supply of the finished product, as well as royalties on the future sales of Veregen(R) in the two countries.

Medigene Announces Earnings Results for the Year Ended 2013; Provides Earnings Guidance for 2014

Medigene announced earnings results for the year ended 2013. In 2013, the company increased its total revenue by 21% and reduced net loss for the year from continued operations by 31%. The company achieved an increase in revenue generated with the drug Veregen(R) of 24% to EUR 4.2 million in 2013 versus EUR 3.4 million of 2012. Total revenue improved by 21% in 2013 to reach EUR 7.6 million versus EUR 6.3 million of 2012. EBITDA loss from continued operations reduced by 12% to reach EUR 8.3 million versus EUR 9.4 million of 2012 and the net loss from continued operations reduced by 31% to EUR 10.3 million versus EUR 14.9 million of 2012. Operating result was negative at EUR 9 million against EUR 16.4 million of prior year. The company expects a double-digit percentage increase in total revenue in 2014. Thereof revenue from Veregen(R) is likely to amount to EUR 5 - EUR 6 million. In addition, Medigene expects to generate revenue consisting mainly of reimbursements of development costs for EndoTAG(R)-1 from SynCore, of non-cash payments from a transaction with Medigene's former drug Eligard as well as milestone payments and pro rata upfront payments from partnerships. The EBITDA loss in 2014 is likely to be reduced to EUR 4 - EUR 6 million.

MediGene AG Auditor Raises 'Going Concern' Doubt

MediGene AG filed its Annual on Mar 27, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGEF:US $6.94 USD +0.84

MDGEF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $203.51 USD -2.16
Hemispherx Biopharma Inc $0.36 USD +0.04
Merck & Co Inc $57.50 USD -0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation MDGEF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at